Cypre Inc. specializes in advanced biotechnology, focusing on the development of innovative 3D in vitro tumor models. Utilizing proprietary hydrogel technology, the company creates complex in vitro models that closely mimic the tumor microenvironment. This approach enables therapeutic innovators to effectively screen and analyze the efficacy and mechanisms of action of their treatments. Cypre's models are designed to address the critical challenge of drug resistance in cancer therapy, providing valuable insights that can accelerate the development of next-generation therapeutics.

The 3D tumor models developed by Cypre are employed by leading pharmaceutical companies, numerous biotech firms, and prominent academic institutions. These models facilitate rapid screening processes, allowing researchers to gain a deeper understanding of how potential therapies interact with cancer cells in a more realistic setting compared to traditional 2D cultures. By partnering with Cypre, organizations can enhance their drug development pipelines and improve outcomes for cancer patients facing treatment resistance.

United States

Cypre is a biotechnology company dedicated to working with therapeutic innovators to overcome drug resistance for cancer patients.

Used by top-10 pharmaceuticals, a multitude of biotechs, and leading academic centers, our 3D in vitro tumor microenvironment models are currently offered as a joint service with Charles River to rapidly screen and generate novel insights into your therapeutic's efficacy and mechanism of action.

Cypre Inc.

Company Details